Dr Jean-Pierre Allain sent a fax to Dr Gunson with a proposal for HCV testing study that supported identifying and approaching all recipients of blood that was "screen positive (repeat reactive)". Read more about Dr Jean-Pierre Allain sent a fax to Dr Gunson with a proposal for HCV testing study that supported identifying and approaching all recipients of blood that was "screen positive (repeat reactive)".
The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting did not discuss Hepatitis C lookback. Read more about The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting did not discuss Hepatitis C lookback.
The agenda for the UK ACTTD meeting included Hepatitis C lookback, but there was no discussion of this recorded in the meeting minutes. Read more about The agenda for the UK ACTTD meeting included Hepatitis C lookback, but there was no discussion of this recorded in the meeting minutes.
The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted that ACVSB had deferred the decision to introduce routine screening for blood donations until April 1990. Read more about The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted that ACVSB had deferred the decision to introduce routine screening for blood donations until April 1990.
The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted the ACVSB agreed the anti-HCV test was a major step forward in identifying those who could transmit the virus, but that routine screening should not commence until the FDA had granted a license and that a cost benefit appraisal should be conducted and discussed with the Department of Health. Read more about The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted the ACVSB agreed the anti-HCV test was a major step forward in identifying those who could transmit the virus, but that routine screening should not commence until the FDA had granted a license and that a cost benefit appraisal should be conducted and discussed with the Department of Health.
The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted the policy regarding anti-Hepatitis C testing and that the focus should be on providing counselling services for those found to be anti-HCV positive. Read more about The minutes of the UK Advisory Committee on Transfusion Transmitted Diseases meeting noted the policy regarding anti-Hepatitis C testing and that the focus should be on providing counselling services for those found to be anti-HCV positive.
A protocol for a pilot study to assess the introduction of routine anti-HCV tests in RTCs was drafted in November 1989 and carried out by Dr Gunson. Read more about A protocol for a pilot study to assess the introduction of routine anti-HCV tests in RTCs was drafted in November 1989 and carried out by Dr Gunson.
Professor Aileen Keel acknowledged in oral evidence that Scotland could have proceeded with a lookback exercise earlier than in the rest of the UK, however it did not. She said that it was "seen as desirable that in such an important area, that the whole of the UK did it roughly at the same time". Read more about Professor Aileen Keel acknowledged in oral evidence that Scotland could have proceeded with a lookback exercise earlier than in the rest of the UK, however it did not. She said that it was "seen as desirable that in such an important area, that the whole of the UK did it roughly at the same time".
Dr Andrzej Rejman said in oral evidence that he could not recall discussion or an internal document within the Department of Health regarding commencing a Hepatitis C lookback when testing became available in the early 1990s. Read more about Dr Andrzej Rejman said in oral evidence that he could not recall discussion or an internal document within the Department of Health regarding commencing a Hepatitis C lookback when testing became available in the early 1990s.
Dr Jack Gillon said in oral evidence that there was "no logic" in deciding not to conduct Hepatitis C lookback as soon as screening became available. His view was that even if there was no available treatment for Hepatitis C infection, individuals should be advised that they had a potentially serious condition. Read more about Dr Jack Gillon said in oral evidence that there was "no logic" in deciding not to conduct Hepatitis C lookback as soon as screening became available. His view was that even if there was no available treatment for Hepatitis C infection, individuals should be advised that they had a potentially serious condition.